THE POSSIBILITIES OF ANXIOLITHIC THERAPY OF ANXIETY-DEPRESSIVE SYNDROME IN PATIENTS ON PROGRAM HEMODIALYSIS


I.S. Belousova, N.N. Borovkov

Department of Hospital Therapy n.a. V.G. Vogralik FSBEI HE NizhSMA of RMH, Nizhny Novgorod
Anxiety-depressive syndrome in patients on program hemodialysis is the most frequent mental disorder in this category of patients. The article describes the results of the use of morpholinoethylthioethoxybenzimidazole dihydrochloride in such patients. It is established that this drug significantly reduces the severity of anxiety and depression, and also improves the quality of life of patients. The four-week therapy with morpholinoethylthioethoxybenzimidazole dihydrochloride is not accompanied by an impact on laboratory indicators used as a control during program hemodialysis.

About the Autors


Corresponding author: I.S. Belousova – extramural postgraduate student at the Department of Hospital Therapy n.a. V.G. Vogralik FSBEI HE NizhSMA of RMH, Nizhny Novgorod; e-mail: Yakobson.irina@bk.ru


Similar Articles


Бионика Медиа